Furthermore, to determine whether AKT is responsible for BRE-induced cell growth and apoptotic resistance in ESCC cells, we used the widely used AKT inhibitor MK2206 to inhibit the activity of AKT in BRE-overexpressing cells. Here, BABAM2 is linked to esophageal squamous cell carcinoma.